Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
14-Aminosalicylic acid extended release granules1件: Aminosalicylic acid1件: Aminosalicylic acid 💬--1件: 96 💬
2Aceneuramic Acid Extended-Release1件: Aceneuramic acid1件: Aceneuramic acid 💬--1件: 30 💬
3Aceneuramic acid extended-release (Ace-ER)1件: Aceneuramic acid1件: Aceneuramic acid 💬--1件: 30 💬
4Aceneuramic Acid Extended-Release Tablets1件: Aceneuramic acid1件: Aceneuramic acid 💬--1件: 30 💬
5ADS-5102 (extended release amantadine HCl)1件: Amantadine1件: Amantadine 💬5件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬1件: 6 💬
6Advagraf prolonged-release hard capsules2件: Manganese citrate (Release),
Tacrolimus		2件: Tacrolimus ,
Tacrolimus 💬		5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 299 💬
7ALKS 8700 Delayed Release (DR)1件: Manganese citrate (Release)---1件: 13 💬
8ALKS 8700 Delayed Release (DR) Capsule1件: Manganese citrate (Release)---1件: 13 💬
9Amantadine HCl Extended Release1件: Amantadine1件: Amantadine 💬5件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬1件: 6 💬
10Amantadine HCl Extended Release Capsule1件: Amantadine1件: Amantadine 💬5件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬1件: 6 💬
11Antioxidant plus Pregabalin
(PREGABALIN EXTENDED RELEASE)		1件: Pregabalin (Pregabalin Extended Release)1件: Pregabalin (PREGABALIN EXTENDED RELEASE) 💬4件: CACNA2D1,
CACNA2D2,
CACNA2D3,
CACNA2D4 💬		7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway 💬1件: 298 💬
12APRISO 375 mg extended-release capsules1件: Manganese citrate (Release)---1件: 97 💬
13Arbaclofen Extended Release Tablets1件: Arbaclofen1件: Arbaclofen 💬2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13 💬
14Asacol (mesalamine) Delayed-release Tablets1件: Mesalazine (Pentasa Extended-release Tablets 250mg)1件: Mesalamine 💬--1件: 97 💬
15Asacol Delayed Release Tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
16Asacol Delayed-Release Tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
17AZD3241 Extended release tablets 100 mg1件: Manganese citrate (Release)---1件: 6 💬
18AZD3241 Extended release tablets 25 mg1件: Manganese citrate (Release)---1件: 6 💬
19Beraprost Sodium 314d Modified Release Tablets1件: Beraprost1件: Beraprost 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
20Beraprost Sodium Modified Release1件: Beraprost1件: Beraprost 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
21Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
22Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
23Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
24Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
25Bydureon 2 mg powder and solvent for prolonged-release suspension2件: Exenatide,
Manganese citrate (Release)		1件: Exenatide 💬1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 6 💬
26Carbidopa and Levodopa Controlled Release Tablets2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
27Carbidopa/Levodopa, immediate release2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
28Continuous Release Dopamine Agonists1件: Dopamine1件: Dopamine 💬5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
29Controlled-release levodopa / carbidopa2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
30Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)7件: Acetate,
Cortisone,
Cortisone acetate,
Dexamethasone,
Hydrocortisone,
Prednisolone,
Prednisone		6件: Hydrocortisone ,
Dexamethasone ,
Prednisolone ,
Prednisone ,
Cortisone acetate ,
Cortisone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
31Cystagon (cysteamine bitartrate) immediate-release capsules1件: Cysteamine (PROCYSBI Delayed-release)1件: Cysteamine 💬--1件: 299 💬
32Cysteamine Bitartrate Delayed-release Capsules1件: Cysteamine (PROCYSBI Delayed-release)1件: Cysteamine 💬--1件: 19 💬
33Cysteamine Bitartrate Delayed-release Capsules (RP103)1件: Cysteamine (PROCYSBI Delayed-release)1件: Cysteamine 💬--1件: 19 💬
34Dalfampridine ER, 10 Mg Oral Tablet, Extended Release1件: Dalfampridine1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
35Deferiprone 600 mg delayed release tablet1件: Deferiprone1件: Deferiprone 💬--1件: 6 💬
36Delayed and extended release mesalazine1件: Mesalazine (Pentasa Extended-release Tablets 250mg)1件: Mesalamine 💬--1件: 97 💬
37Delayed Release 6 mercaptopurine1件: Mercaptopurine2件: Mercaptopurine ,
Mercaptopurine 💬		1件: HPRT1 💬4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 96 💬
38Delayed Release 6MP or Calcitriol vs. Purinethol1件: Calcitriol1件: Calcitriol 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96 💬
39Diazoxide choline controlled-release tablet2件: Choline (Timed Release B Complex 100 Srt),
Diazoxide		2件: Diazoxide ,
Choline 💬		2件: ABCC8,
KCNJ11 💬		4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus 💬1件: 193 💬
40Dual release hydrocortisone (plenadren)1件: Hydrocortisone1件: Hydrocortisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
41Efmody 10 mg modified release hard capsules2件: Hydrocortisone,
Manganese citrate (Release)		1件: Hydrocortisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
42Efmody 5 mg modified release hard capsules2件: Hydrocortisone,
Manganese citrate (Release)		1件: Hydrocortisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
43Epilim Chrono 200 Controlled Released tablets----1件: 256 💬
44Epilim Chrono 300 Controlled Released tablets----1件: 256 💬
45Epilim Chrono 500 Controlled Released tablets----1件: 256 💬
46Exenatide extended release 2mg (Bydureon)1件: Exenatide1件: Exenatide 💬1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 6 💬
47Extended release dipyridamole 200mg/aspirin 25mg2件: Acetylsalicylic acid (Aspirin Coated for Delayed Release Extra Strength),
Dipyridamole (Asprin and Extended-release Dipyridamole)		2件: Aspirin ,
Dipyridamole 💬		4件: PDE4A,
PDE5A,
PTGS1,
PTGS2 💬		28件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Morphine addiction, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Purine metabolism, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 49 💬
48Extended release fampridine1件: Dalfampridine1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
49Extended Release Melatonin1件: Melatonin (Melatonin Rapid Release Gelcaps 10 mg)1件: Melatonin 💬2件: MTNR1A,
MTNR1B 💬		2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬1件: 6 💬
50Extended-release oxycodone1件: Oxycodone (Oxycodone Hydrochloride Controlled-release)1件: Oxycodone 💬3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 13 💬
51Extended-release quetiapine fumarate1件: Quetiapine (Quetiapine Extended Release)1件: Quetiapine 💬2件: DRD2,
HTR2A 💬		11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway 💬1件: 13 💬
52Fampyra 10 mg prolonged-release tablets2件: Dalfampridine,
Manganese citrate (Release)		1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
53Fampyra 10mg prolonged release tablets2件: Dalfampridine,
Manganese citrate (Release)		1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
54Firategrast immediate release tablet1件: Firategrast1件: Firategrast 💬1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13 💬
55Firategrast modified release tablet1件: Firategrast1件: Firategrast 💬1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13 💬
56Guanfacine Extended Release1件: Guanfacine (Guanfacine Extended-Release)1件: Guanfacine 💬1件: ADRA2A 💬2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 193 💬
57Guanfacine extended release (GXR)1件: Guanfacine (Guanfacine Extended-Release)1件: Guanfacine 💬1件: ADRA2A 💬2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 193 💬
58Hydrocortisone Modified Release Capsules1件: Hydrocortisone1件: Hydrocortisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
59IBD98-M Delayed-release Capsules1件: Manganese citrate (Release)---1件: 97 💬
60Immediate release carbidopa/levodopa2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
61Immediate Release carbidopa/levodopa 10/100 mg2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
62Immediate Release carbidopa/levodopa 25/100 mg2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
63Immediate Release Melatonin1件: Melatonin (Melatonin Rapid Release Gelcaps 10 mg)1件: Melatonin 💬2件: MTNR1A,
MTNR1B 💬		2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬1件: 6 💬
64KVD824 300 mg Modified Release Tablets1件: Manganese citrate (Release)---1件: 65 💬
65LAMOTRIGINE
(LAMOTRIGINE EXTENDED RELEASE)		1件: Lamotrigine (Lamotrigine Extended Release)1件: Lamotrigine (LAMOTRIGINE EXTENDED RELEASE) 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬5件: 13, 34, 38, 114, 144 💬
66Lamotrigine - generic product
(LAMOTRIGINE EXTENDED RELEASE)		1件: Lamotrigine (Lamotrigine Extended Release)1件: Lamotrigine (LAMOTRIGINE EXTENDED RELEASE) 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 38 💬
67Lamotrigine 25Mg Oral Tablet, Extended Release1件: Lamotrigine (Lamotrigine Extended Release)1件: Lamotrigine (LAMOTRIGINE EXTENDED RELEASE) 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 114 💬
68Lamotrigine dispers
(LAMOTRIGINE EXTENDED RELEASE)		1件: Lamotrigine (Lamotrigine Extended Release)1件: Lamotrigine (LAMOTRIGINE EXTENDED RELEASE) 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 34 💬
69Lamotrigine extended release tablets1件: Lamotrigine (Lamotrigine Extended Release)1件: Lamotrigine (LAMOTRIGINE EXTENDED RELEASE) 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 13 💬
70Levetiracetam
(LEVETIRACETAM EXTENDED RELEASE)		1件: Levetiracetam (LEVETIRACETAM Extended-release)1件: Levetiracetam (LEVETIRACETAM EXTENDED RELEASE) 💬1件: SV2A 💬1件: ECM-receptor interaction 💬5件: 2, 4, 6, 13, 307 💬
71Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
72Levodopa CR (controlled release)1件: Levodopa1件: Levodopa 💬5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
73Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
74Levodopa-carbidopa Immediate Release (LC-IR) Tablets2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
75Levodopa-Carbidopa Multilayer Extended Release Tablet2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
76Lodotra (delayed release prednisolone)1件: Prednisolone1件: Prednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 41 💬
77LPM3770164 sustained release tablet1件: Manganese citrate (Release)---1件: 8 💬
78LPM3770164 sustained release tablet simulant1件: Manganese citrate (Release)---1件: 8 💬
79LT-02 (modified-release PC pellets)1件: Manganese citrate (Release)---1件: 97 💬
80LY03003 ( Rotigotine, extended-release microspheres)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
81LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
82LY03003(Rotigotine,extended-release microspheres)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
83Mesalamine Delayed Release Tablets 400mg2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
84Mesalazine slow-release granules1件: Mesalazine (Pentasa Extended-release Tablets 250mg)1件: Mesalamine 💬--1件: 97 💬
85Mesalazine Sustained-Release Tablets1件: Mesalazine (Pentasa Extended-release Tablets 250mg)1件: Mesalamine 💬--1件: 96 💬
86Methylphenidate modified release1件: Methylphenidate (Methylphenidate Hydrochloride Extended Release)1件: Methylphenidate 💬2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
87Methylphenidate modified release 20 mg1件: Methylphenidate (Methylphenidate Hydrochloride Extended Release)1件: Methylphenidate 💬2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
88Methylphenidate modified release 30 mg1件: Methylphenidate (Methylphenidate Hydrochloride Extended Release)1件: Methylphenidate 💬2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
89Methylphenidate modified release 40 mg1件: Methylphenidate (Methylphenidate Hydrochloride Extended Release)1件: Methylphenidate 💬2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
90Mezavant Gastro-resistant, prolonged release tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
91Mezavant XL 1200 mg gastro-resistant prolonged release tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
92Mezavant XL 1200 mg gastro-resistant, prolonged release tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
93Mezavant XL 1200 mg gastro-resistant, prolonged release tablets.2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
94Mezavant XL 1200mg gastro-resistant, prolonged release tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
95Mezavant XL Gastro-resistant, prolonged release tablets2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
96MG01CI extended-release tablet1件: Manganese citrate (Release)---1件: 206 💬
97Mirapexin extended release various strengths2件: Manganese citrate (Release),
Pramipexole (Pramipexole Dihydrochloride Extended-Release)		1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
98Modified-release phosphatidylcholine2件: Lecithin,
Manganese citrate (Release)		1件: Lecithin 💬--1件: 97 💬
99Nalbuphine Extended-Release (ER) Tablets1件: Nalbuphine1件: Nalbuphine 💬3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 85 💬
100Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)1件: Naproxen (Naproxen delayed release)1件: Naproxen 💬2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46 💬
101Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)1件: Naproxen (Naproxen delayed release)1件: Naproxen 💬2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46 💬
102Octreotide LAR / Sandostatin LAR (LAR=long acting release)1件: Octreotide1件: Octreotide 💬1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
103Oral treprostinil (UT-15C) Sustained Release Tablets1件: Treprostinil1件: Treprostinil 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
104Oxycodone naloxone prolonged release tablets2件: Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226 💬
105Oxycodone/naloxone prolonged release t3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226 💬
106Oxycodone/Naloxone Prolonged Release tablets2件: Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6 💬
107Oxycodone/naloxone prolonged release tablets 10 mg /5 mg3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6 💬
108Oxycodone/naloxone prolonged release tablets 10/5 mg3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226 💬
109Oxycodone/naloxone prolonged release tablets 20 mg /10 mg3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6 💬
110Oxycodone/naloxone prolonged release tablets 20/10 mg3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226 💬
111Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6 💬
112Oxycodone/naloxone prolonged release tablets 5/2.5 mg3件: Manganese citrate (Release),
Naloxone,
Oxycodone (Oxycodone Hydrochloride Controlled-release)		2件: Oxycodone ,
Naloxone 💬		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226 💬
113Pancrelipase Delayed Release1件: Pancrelipase1件: Pancrelipase 💬--1件: 299 💬
114Pancrelipase Delayed Release Capsule1件: Pancrelipase1件: Pancrelipase 💬--2件: 298, 299 💬
115Pentasa 2g sachet prolonged release granules (95%)2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
116Pentasa Compact 2g, granulate with prolonged release2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
117Pentasa Compact 4g, granulate with prolonged release2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
118Pentasa prolonged release granules 2g2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
119Pentasa Sachet 1 g prolonged release granules2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 96 💬
120Plenadren 20 mg modified-release tablets2件: Hydrocortisone,
Manganese citrate (Release)		1件: Hydrocortisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 78 💬
121Plenadren 5 mg modified-release tablets2件: Hydrocortisone,
Manganese citrate (Release)		1件: Hydrocortisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 78 💬
122Pramipexol Extended Release1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
123Pramipexol Immediate Release1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
124Pramipexole dihydrochloride extended-release tablets1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
125Pramipexole dihydrochloride monohydrate extended release2件: Manganese citrate (Release),
Pramipexole (Pramipexole Dihydrochloride Extended-Release)		1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
126Pramipexole Extended Release1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
127Pramipexole extended release tablet1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
128Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
129Pramipexole Immediate Release1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
130Pramipexole immediate release tablet1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
131Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)1件: Pramipexole (Pramipexole Dihydrochloride Extended-Release)1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
132Pregabalin
(PREGABALIN EXTENDED RELEASE)		1件: Pregabalin (Pregabalin Extended Release)1件: Pregabalin (PREGABALIN EXTENDED RELEASE) 💬4件: CACNA2D1,
CACNA2D2,
CACNA2D3,
CACNA2D4 💬		7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway 💬5件: 13, 36, 46, 70, 298 💬
133Pregabalin 75mg
(PREGABALIN EXTENDED RELEASE)		1件: Pregabalin (Pregabalin Extended Release)1件: Pregabalin (PREGABALIN EXTENDED RELEASE) 💬4件: CACNA2D1,
CACNA2D2,
CACNA2D3,
CACNA2D4 💬		7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway 💬1件: 70 💬
134Prolonged release tablet1件: Manganese citrate (Release)---1件: 6 💬
135Prolonged-release Fampridine1件: Dalfampridine1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
136Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die1件: Ranolazine1件: Ranolazine 💬--1件: 58 💬
137RAYOS (delayed-release prednisone)1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46 💬
138Release1件: Manganese citrate (Release)---12件: 6, 8, 13, 46, 65, 78, 81, 96, 97, 206, 226, 299 💬
139Requip prolonged release2件: Manganese citrate (Release),
Ropinirole		1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
140Requip XL prolonged-release2件: Manganese citrate (Release),
Ropinirole		1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
141Retarded release phosphatidylcholine1件: Lecithin1件: Lecithin 💬--1件: 97 💬
142Retarded Release Phosphatidylcholine (rPC)1件: Lecithin1件: Lecithin 💬--1件: 97 💬
143Rifaximin Delayed Release (DR)1件: Rifaximin1件: Rifaximin 💬--1件: 96 💬
144Rifaximin delayed release 400 mg film coated tablet1件: Rifaximin1件: Rifaximin 💬--1件: 96 💬
145Rifaximin delayed release tablets1件: Rifaximin1件: Rifaximin 💬--1件: 96 💬
146Ropinirole controlled-release (REQUIP CR) for RLS1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
147Ropinirole hydrochloride extended-release tablet1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
148Ropinirole hydrochloride extended-release tablet placebo1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
149Ropinirole hydrochloride prolonged release2件: Manganese citrate (Release),
Ropinirole		1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
150Ropinirole immediate release1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
151Ropinirole Prolonged release1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
152Ropinirole prolonged release/extended release(PR/XR)1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
153Rosiglitazone Extended Release Tablets1件: Rosiglitazone1件: Rosiglitazone 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 46 💬
154Rotigotine, extended-release microspheres1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
155Salofalk 3g gastro-resistant prolonged-release granules2件: Manganese citrate (Release),
Mesalazine (Pentasa Extended-release Tablets 250mg)		1件: Mesalamine 💬--1件: 97 💬
156Sinemet CR 25Mg-100Mg Extended-Release Tablet3件: Carbidopa,
Levodopa,
Manganese citrate (Release)		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
157Sinemet® controlled release (Carbidopa/levodopa)2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
158SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine1件: Mesalazine (Pentasa Extended-release Tablets 250mg)1件: Mesalamine 💬--1件: 97 💬
159Sustained release growth hormone1件: Somatotropin---1件: 78 💬
160Sustained-release oral dalfampridine1件: Dalfampridine1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
161Sustained-release recombinant human GH (SR-rhGH)1件: Somatotropin---1件: 78 💬
162Tacrolimus prolonged-release hard capsules2件: Manganese citrate (Release),
Tacrolimus		2件: Tacrolimus ,
Tacrolimus 💬		5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 299 💬
163Targinact 10 mg/5 mg prolonged-release tablets1件: Manganese citrate (Release)---2件: 6, 226 💬
164Targinact 20 mg/10 mg prolonged-release tablets1件: Manganese citrate (Release)---1件: 6 💬
165Targinact 20mg/10 mg prolonged-release tablets1件: Manganese citrate (Release)---1件: 226 💬
166Targinact 5 mg/2.5 mg prolonged-release tablets1件: Manganese citrate (Release)---1件: 6 💬
167Targinact 5mg/2.5 mg prolonged-release tablets1件: Manganese citrate (Release)---1件: 226 💬
168Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
169WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
170WD-1603 Carbidopa-Levodopa Extended-Release Tablets2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
171WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
172Xeljanz® 11mg Prolonged Release Tablet2件: Manganese citrate (Release),
Tofacitinib		1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬